Orolabial Lymphogranuloma Venereum, Michigan, USA

Ilyas, Sahrish; Richmond, Deborah; Burns, Gerald; Bowden, Katherine E.; Workowski, Kimberly A.; Kersh, Ellen N.; Chandrasekar, Pranatharthi H.

doi:10.3201/eid2511.190819

Cited by 4 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LGV-associated lymphadenopathy can be severe, with bubo formation from fluctuant or suppurative inguinal or femoral lymphadenopathy. Oral ulceration can occur and might be associated with cervical adenopathy (549)(550)(551). Persons with genital or colorectal LGV lesions can also experience secondary bacterial infection or can be infected with other sexually and nonsexually transmitted pathogens.…”

Section: Lymphogranuloma Venereummentioning

confidence: 99%

“…However, these tests are not widely available, and results are not typically available in a time frame that would influence clinical management. Therefore, diagnosis is based on clinical suspicion, epidemiologic information, and a C. trachomatis NAAT at the symptomatic anatomic site, along with exclusion of other etiologies for proctocolitis, inguinal lymphadenopathy, or genital, oral, or rectal ulcers ( 551 , 552 ). Genital or oral lesions, rectal specimens, and lymph node specimens (i.e., lesion swab or bubo aspirate) can be tested for C. trachomatis by NAAT or culture.…”

Section: Diseases Characterized By Genital Anal or Perianal Ulcersmentioning

confidence: 99%

See 1 more Smart Citation

Sexually Transmitted Infections Treatment Guidelines, 2021

Workowski¹,

Bachmann²,

Chan³

et al. 2021

MMWR Recomm. Rep.

1,732

2,621

View full text Add to dashboard Cite

These guidelines for the treatment of persons who have or are at risk for sexually transmitted infections (STIs) were updated by CDC after consultation with professionals knowledgeable in the field of STIs who met in Atlanta, Georgia, June 11-14, 2019. The information in this report updates the 2015 guidelines. These guidelines discuss 1) updated recommendations for treatment of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis; 2) addition of metronidazole to the recommended treatment regimen for pelvic inflammatory disease; 3) alternative treatment options for bacterial vaginosis; 4) management of Mycoplasma genitalium; 5) human papillomavirus vaccine recommendations and counseling messages; 6) expanded risk factors for syphilis testing among pregnant women; 7) one-time testing for hepatitis C infection; 8) evaluation of men who have sex with men after sexual assault; and 9) two-step testing for serologic diagnosis of genital herpes simplex virus. Physicians and other health care providers can use these guidelines to assist in prevention and treatment of STIs. BOX 1. The Five P's approach for health care providers obtaining sexual histories: partners, practices, protection from sexually transmitted infections, past history of sexually transmitted infections, and pregnancy intention Additional information about external condoms is available at https://www.cdc.gov/condomeffectiveness. Internal CondomsCondoms for internal vaginal use, also known as female condoms, are available worldwide (e.g., the FC2 Female Condom, Reddy condom, Cupid female condom, and Woman's condom) (31,32). Use of internal condoms can provide protection from acquisition and transmission of STIs, although data are limited. Internal condoms are more costly compared with external condoms; however, they offer the advantage of being controlled by the receptive partner as an STI and HIV prevention method, and the newer versions might be acceptable to all persons. Although the internal condom also has been used during receptive anal intercourse, efficacy associated with this practice remains unknown (33). Additional information about the internal condom is available at http://www.ashasexualhealth. org/pdfs/Male_and_Female_Condoms.pdf. Cervical DiaphragmsIn observational studies, diaphragm use has been demonstrated to protect against cervical gonorrhea, chlamydia, and trichomoniasis (34). However, a trial examining the effect of a diaphragm plus lubricant on HIV acquisition among women in Africa reported no additional protective effect when compared with the use of male condoms alone. Likewise, no difference by study arm in the rate of acquisition of chlamydia, gonorrhea, or herpes occurred (35,36). Diaphragms should not be relied on as the sole source of protection against HIV and other STIs.

show abstract

Section: Lymphogranuloma Venereummentioning

confidence: 99%

Section: Diseases Characterized By Genital Anal or Perianal Ulcersmentioning

confidence: 99%

Sexually Transmitted Infections Treatment Guidelines, 2021

Workowski¹,

Bachmann²,

Chan³

et al. 2021

MMWR Recomm. Rep.

1,732

2,621

View full text Add to dashboard Cite

show abstract

“…However, these tests are not widely available, and results are not typically available in a time frame that would influence clinical management. Therefore, diagnosis is based on clinical suspicion, epidemiologic information, and a CT Nucleic acid Amplification Test (NAAT) at the symptomatic anatomic site, along with the exclusion of other etiologies for proctocolitis, inguinal lymphadenopathy, or genital, oral, or rectal ulcers [26,27]. Genital or oral lesions, rectal specimens, and lymph node specimens (i.e., lesion swab or bubo aspirate) can be tested for CT by NAAT or culture.…”

Section: Chlamydia Trachomatismentioning

confidence: 99%

Treatment of Bacterial Sexually Transmitted Infections in Resource-Limited Settings

Amadi¹,

Ononuju²,

Okoeguale³

et al. 2023

Infectious Diseases

View full text Add to dashboard Cite

Globally, bacterial sexually transmitted infections (STIs) are a major health challenge. It is more challenging in resource-limited settings, where diagnostic capabilities are limited, health insurance is almost nonexistent and medical bills are settled out-of-pocket. In resource-limited settings, most clinicians adopt the syndromic case management approach for effective treatment due to the paucity of resources. The highest levels of multidrug resistant bacterial STIs have been found in resource-limited countries. The reasons are complex and include poor quality of health services, high burden of disease, lack of accessible, accurate, and confirmed diagnostic assays, ineffective regulations, overuse of antibiotics, inappropriate dosing, and lack of knowledge about the risks of microbial resistance. This chapter thus brings to the fore the challenges of treating bacterial sexually transmitted infections in resource-poor settings and the current evidence on the topic for scholars, researchers, and practitioners.

show abstract